Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...

Strand Therapeutics has raised $153 million in second-round financing that will be used to move its programmable mRNA ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.

It reasoned that Pfizer Inc. (NYSE:PFE) is entering into a competitive avenue with its PD1-VEGF bispecific antibody, SSGJ-707, primarily because it faces competition from other major ...

Pfizer Inc. announced the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of ...

SSGJ-707 is currently in clinical trials in China for non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and gynecological tumors. Interim Phase 2 results for NSCLC were recently ...